Spontaneous femoral shaft fracture after long-term alendronate

Age and Ageing

Volumn 38, Issue 5, 2009, Pages 625-626

  Ali, Tamir ^a   Jay, Roger H ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Alendronate; Elderly; Femur; Fracture; Spontaneous

Indexed keywords

ALENDRONIC ACID; CARBOXY TERMINAL TELOPEPTIDE;

AGED; ARTICLE; BONE RADIOGRAPHY; BONE SCINTISCANNING; BONE TURNOVER; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; FEMALE; FEMUR SHAFT FRACTURE; FRAGILITY FRACTURE; HUMAN; LEG PAIN; LONG TERM CARE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; VERTEBRA FRACTURE;

AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; BONY CALLUS; FEMALE; FEMORAL FRACTURES; FRACTURES, SPONTANEOUS; HUMANS;

EID: 69449085642     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afp106     Document Type: Article

References (10)

1. Tonino RP, Meunier PJ, Emkey R et al. Phase III Osteoporosis Treatment Study Group. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000; 85: 3109-15.
2. Black DM, Thompson DE, Bauer DC et al. FIT Research Group. Fracture risk reductionwith alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000; 85: 4118-24.
3. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358: 1304-6.
4. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294-301.
5. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28: 524-31.
6. Cheung RK, Leung KK, Lee KC, Chow TC. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 2007; 13: 485-9.
7. Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006; 61: 31-3.
8. Goh SK, Yang KY, Koh JS et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br 2007; 89: 349-53.
9. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008; 22: 346-50.
10. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005; 90: 1897-9.